WCG Wealth Advisors LLC Purchases 224 Shares of IQVIA Holdings Inc. (NYSE:IQV)

WCG Wealth Advisors LLC boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 1.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,497 shares of the medical research company’s stock after acquiring an additional 224 shares during the quarter. WCG Wealth Advisors LLC’s holdings in IQVIA were worth $3,700,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of IQV. First Foundation Advisors boosted its position in shares of IQVIA by 3.8% during the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after buying an additional 43 shares during the last quarter. Team Hewins LLC raised its holdings in shares of IQVIA by 5.0% during the first quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock valued at $246,000 after purchasing an additional 46 shares during the last quarter. Invera Wealth Advisors LLC raised its holdings in shares of IQVIA by 0.3% during the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after purchasing an additional 46 shares during the last quarter. Covestor Ltd boosted its holdings in IQVIA by 45.3% in the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after purchasing an additional 48 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund grew its position in IQVIA by 0.3% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after purchasing an additional 48 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 1.1 %

Shares of IQV opened at $242.67 on Thursday. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The company’s fifty day moving average is $239.74 and its 200 day moving average is $234.18. The stock has a market capitalization of $44.21 billion, a PE ratio of 33.15, a P/E/G ratio of 2.24 and a beta of 1.49.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. During the same quarter last year, the firm earned $2.22 EPS. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Insider Activity

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on IQV shares. Evercore ISI raised their target price on IQVIA from $230.00 to $270.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 23rd. Robert W. Baird increased their price target on shares of IQVIA from $235.00 to $251.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 23rd. UBS Group raised their target price on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. The Goldman Sachs Group assumed coverage on IQVIA in a research report on Thursday, June 6th. They set a “buy” rating and a $270.00 price objective on the stock. Finally, Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $266.67.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.